Eppendorf Renews Founding Sponsorship with LabCentral
Empowering innovative biotech startups
The globally active Eppendorf Group proudly announces the 5-year partnership renewal with LabCentral, a life sciences incubator, dedicated to empowering innovative biotech startups. As a Partner since 2014 and Founding Sponsor since 2019, the Eppendorf Group continues its commitment to fostering scientific breakthroughs and supporting the next generation of biotech innovators.
Strategically placed Eppendorf equipment and consumables at LabCentral enables reliable results for startups, contributing to scientific milestones to being reached quicker.
©LabCentral
"Eppendorf is proud to continue its relationship as a Founding Sponsor with LabCentral, affirming our shared vision for advancing scientific excellence and empowering researchers to make groundbreaking discoveries", says Dennis Barger, President Market Region Americas, Eppendorf. "Together, we continue to shape the future of life sciences, where collaboration is the catalyst for transformative breakthroughs."
LabCentral is a community of entrepreneurs and scientists dedicated to creating the next generation of groundbreaking science and technology. The Eppendorf Group is a leading life science company that develops, produces, and distributes systems for use in laboratories around the world. Through the partnership, the Eppendorf Group provides a range of equipment, including freezers, shakers, incubators, cyclers, centrifuges, automation, bioprocess, and pipettes, placed within LabCentral's shared facilities. This provides startups immediate access to high quality instrumentation, ensuring they can run experiments day one of residency.
"As a longtime strategic Founding Sponsor to LabCentral, Eppendorf has built a strong reputation for excellence both inside our labs as well as in our resident community", shares Johannes Fruehauf, MD, PhD, President and Executive Director LabCentral. "We are thrilled to extend this collaboration towards our shared mission to improve human health by building biotechs better, faster, and more efficiently."
LabCentral occupies six sites in Massachusetts, USA, continually expanding since being established in 2013. 21% of biopharma Series A funds in 2022 in the US has been awarded to companies affiliated with LabCentral and its resident and alumni companies have raised nearly $23 billion in total funding, creating 5,800 new jobs since 2013. The premier shared lab community is home to more than 100 companies ranging from a single employee to teams of 30 or more. LabCentral offers an ideal space and infrastructure for biotech startups to focus on building their company and developing their science. The future of medicine starts at this leading incubator with the resident innovators and Eppendorf as a premium solutions provider.
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
Something is happening in the life science industry ...
This is what true pioneering spirit looks like: Plenty of innovative start-ups are bringing fresh ideas, lifeblood and entrepreneurial spirit to change tomorrow's world for the better. Immerse yourself in the world of these young companies and take the opportunity to get in touch with the founders.
